A micro-cap MS neuroprotection bet combining a Phase 2 Lucid-MS catalyst, a consumer-royalty runway from unbuzzd™, and a high-volatility litigation/crypto optionality layer.
Overview
Quantum BioPharma (QNTM) is a Toronto-based clinical-stage biotech that has recently repositioned from its predecessor FSD Pharma via a formal rebrand and a 65:1 share consolidation, reframing the company around “high-science” CNS and inflammatory drug development. Operations are split between (1) Biopharmaceutical Innovation—anchored by Lucid-MS, a patented neuroprotective candidate for Multiple Sclerosis aimed at preventing and potentially reversing myelin degradation—and (2) Strategic Investments, including secured residential loans and a treasury function that holds liquid digital assets such as Bitcoin. While the company has no meaningful recurring drug revenue today, it has built a transitional, diversified value model by spinning out the consumer supplement unbuzzd™ into Unbuzzd Wellness, retaining ~20% equity and a 7% gross royalty (until $250M is recouped, then 3% in perpetuity). This structure is intended to generate nearer-term, potentially non-dilutive cash flow while management concentrates capital on Lucid-MS’s Phase 2 pathway. Financially, the company reports ~$11.3M in cash/digital assets, reduced liabilities, and a stated runway to January 2028, but it carries a significant dilution overhang from prior financings and settlement-driven issuance. The investment case is therefore a high-volatility mix of Phase 2 clinical optionality, consumer-royalty scaling, and litigation upside (a $700M lawsuit) against a micro-cap valuation backdrop (~$22M market cap).